NCT03138720View on ClinicalTrials.gov

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

March 3, 2024

Study Completion Date

August 1, 2025

Conditions
Resectable Pancreatic CancerUnresectable Pancreatic CancerPancreatic AdenocarcinomaNeoadjuvant Pancreatic Cancer
Interventions
DRUG

Paclitaxel Protein Bound (Abraxane)

Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
lead

HonorHealth Research Institute

OTHER